Chicago, ILLINOIS5 Active Studies

Duchenne Muscular Dystrophy Clinical Trials in Chicago, ILLINOIS

Find 5 actively recruiting duchenne muscular dystrophy clinical trials in Chicago, ILLINOIS. Connect with local research sites and explore new treatment options.

5
Active Trials
4
Sponsors
171
Enrolling

Recruiting Duchenne Muscular Dystrophy Studies in Chicago

RecruitingChicago, ILLINOISNCT05693142

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

RGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is...

65 participants
REGENXBIO Inc.
View Study Details
RecruitingChicago, ILLINOISNCT06138639

A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

This is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dy...

40 participants
Solid Biosciences Inc.
View Study Details
RecruitingChicago, ILLINOISNCT05412394

Once Weekly Infant Corticosteroid Trial for DMD

The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg/kg/week) will be equally effective to the 10mg/kg/week dose....

26 participants
Anne M. Connolly
View Study Details
RecruitingChicago, ILLINOISNCT05996003

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skip...

20 participants
NS Pharma, Inc.
View Study Details
RecruitingChicago, ILLINOISNCT06053814

NS-050/NCNP-03 in Boys With DMD (Meteor50)

This is a Phase 1/2 study of Multiple-Ascending Dose (MAD) levels for 12 weeks of treatment followed by 24 weeks of open-label treatment with a selected dose of NS-050/NCNP-03 administered once weekly...

20 participants
NS Pharma, Inc.
View Study Details

About Duchenne Muscular Dystrophy Clinical Trials in Chicago

Duchenne muscular dystrophy is a severe genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys. It is caused by mutations in the dystrophin gene. Treatment includes corticosteroids, gene therapies, and supportive care to maintain mobility and function.

There are currently 5 duchenne muscular dystrophy clinical trials recruiting participants in Chicago, ILLINOIS. These studies are seeking a combined 171 participants. Research is being sponsored by REGENXBIO Inc., Solid Biosciences Inc., Anne M. Connolly and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Duchenne Muscular Dystrophy Clinical Trials in Chicago — FAQ

Are there duchenne muscular dystrophy clinical trials in Chicago?

Yes, there are 5 duchenne muscular dystrophy clinical trials currently recruiting in Chicago, ILLINOIS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What duchenne muscular dystrophy treatments are being tested?

The 5 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for duchenne muscular dystrophy.

Data updated March 2, 2026 from ClinicalTrials.gov